Lundbeck was the European Union’s fist ‘pay-for-delay’ case in the pharmaceutical sector. On the 8th of September the General Court accepted the Commission’s judgement. With this, the European Commission articulated that pharma ‘pay-for-delay’ agreements breach EU antitrust rules. We are pleased to be joined by Theofanis Christoforou, Director, Principal Legal Adviser, Competition & Mergers, Legal Service - European Commission, to offer his reflections on the General Court judgement.
Director, Principal Legal Adviser, Competition & Mergers, Legal Service | European Commission
Theofanis Christoforou has been with the European Commission Legal Service for more than 30 years, where he is the Director in charge of competition law and merger control. He has obtained law degrees from the Universities of Thessaloniki (JD, 1977), University College London (LLM, 1979), College of Europe (1981) and Harvard Law School (LLM, 1988). He has acted as legal counsel for the European Commission in many cases before the Court of Justice and the General Court on a variety of issues of European Union law, competition law and international trade law. He has also handled several cases before the GATT 47 panels and the WTO dispute settlement system, and has participated in the Uruguay Round trade negotiations as a legal adviser to the European Commission. Before joining the European Commission he practiced law for a number of years and is a member of the Bar of Thessaloniki, Greece. His main areas of academic research currently focus on the interface of law, economics, science and adjudication. He has published a number of articles on issues of general EU law, competition law, international trade law and environmental law.